Anebulo Pharmaceuticals
ANEB
ANEB was delisted on the 27th of February, 2026.
19 hedge funds and large institutions have $91.6M invested in Anebulo Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 4 closing their positions.
65% more capital invested
Capital invested by funds: $55.5M → $91.6M (+$36M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
0.03% less ownership
Funds ownership: 54.08% → 54.06% (-0.03%)
10% less funds holding
Funds holding: 21 → 19 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$295K |
| 2 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
+$68.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$55.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.82K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$319K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$47.9K |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$47.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$30.5K |
| 5 |
Renaissance Technologies
New York
|
-$7.76K |
ANEB Hedge Fund Activity: Q4 2025 in Review
19 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Anebulo Pharmaceuticals (ANEB) for Q4 2025, worth a combined $91.6M — up 65% from $55.5M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ANEB and 2 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $295K. The largest seller was Ikarian Capital, cutting an estimated $319K.
- 19 institutional investors held Anebulo Pharmaceuticals (ANEB) as of Q4 2025, down from 21 in Q3 2025.
- Funds reported $91.6M of Anebulo Pharmaceuticals stock for Q4 2025, up 65% quarter-over-quarter.
- 2 funds opened new Anebulo Pharmaceuticals positions in Q4 2025 and 4 closed out, a net change of -2 holders.
- The largest Anebulo Pharmaceuticals buyer in Q4 2025 was Vanguard Group, an estimated $295K added.
- The largest Anebulo Pharmaceuticals seller in Q4 2025 was Ikarian Capital, an estimated $319K sold.
Based on aggregated 13F filings for Q4 2025.